Sleep Duration Reference Ranges
Standard reference data display of sleep duration ranges by age group. Primary source: National Sleep Foundation (NSF) 2015 multidisciplinary consensus panel. Adult strata endorsed by American Academy of Sleep Medicine (AASM) and Sleep Research Society (SRS) 2016 joint position. Each age row contains three classification columns: Recommended (≥80% expert-panel agreement), May Be Appropriate (50-79% agreement), and Not Recommended (≥80% agreement for contraindication). Select an age stratum below to highlight the corresponding row.
Age Stratum Selector
| Age Group | Recommended (h) | May Be Appropriate (h) | Not Recommended (h) |
|---|---|---|---|
| 0–3 months Newborn |
14 – 17 | 11 – 13 or 18 – 19 | < 11 or > 19 |
| 4–11 months Infant |
12 – 15 | 10 – 11 or 16 – 18 | < 10 or > 18 |
| 1–2 years Toddler |
11 – 14 | 9 – 10 or 15 – 16 | < 9 or > 16 |
| 3–5 years Preschool |
10 – 13 | 8 – 9 or 14 | < 8 or > 14 |
| 6–13 years School Age · AASM/SRS endorsed |
9 – 11 | 7 – 8 or 12 | < 7 or > 12 |
| 14–17 years Teen · AASM/SRS endorsed |
8 – 10 | 7 or 11 | < 7 or > 11 |
| 18–64 years Adult · AASM/SRS endorsed |
7 – 9 | 6 or 10 | < 6 or > 10 |
| ≥65 years Older Adult · AASM/SRS endorsed |
7 – 8 | 5 – 6 or 9 | < 5 or > 9 |
All values are total sleep time (TST) in hours per 24-hour period. NSF 2015 consensus panel output, AASM/SRS 2016 endorsement for school-age through older-adult strata.
NSF 2015 Consensus Panel Methodology
The 2015 National Sleep Foundation sleep duration recommendations were produced through a formal multistep consensus process designed to minimize bias and maximize transparency. The NSF convened an expert panel of 18 members with disciplinary representation across sleep medicine, pulmonology, neurology, pediatrics, neonatology, geriatrics, exercise physiology, methodology, epidemiology, and biostatistics. Panel members completed a standardized conflict-of-interest disclosure process prior to participation, and members with substantive conflicts were excluded from voting on affected strata.
The evidence base was assembled via a systematic literature search through June 2014, encompassing PubMed, MEDLINE, EMBASE, and the Cochrane Library. Search terms included combinations of "sleep duration," "sleep hours," "mortality," "morbidity," "performance," "development," "cognition," "cardiovascular," "diabetes," "obesity," and "all-cause mortality." Abstract screening and full-text review were conducted in duplicate. Data were extracted on study design, sample size, population characteristics, sleep duration exposure assessment method, and outcome associations. The panel graded the strength of each body of evidence using a modified version of the RAND/UCLA Appropriateness Method rating scale, which incorporates both the quality of research design and the consistency of findings across studies.
Voting proceeded through three sequential rounds. In Round 1, panelists anonymously rated the appropriateness of each integer hour duration (from 0 through 24) for each age stratum on a 1-9 scale, separately for three outcome domains: general health and mortality, cognitive function and performance, and mood and quality of life. Round 2 followed a structured face-to-face meeting where panelists reviewed aggregated Round 1 results, discussed areas of disagreement, and reconsidered their ratings in a second anonymous ballot. Round 3 was a final anonymous confirmation vote. For a duration to be classified as Recommended, ≥80% of panelists' ratings in the final round had to fall within the 7-9 appropriateness range (appropriate). May Be Appropriate required 50-79% of ratings in the 7-9 range. Not Recommended required ≥80% of ratings in the 1-3 range (inappropriate). Inter-rater agreement statistics (kappa and intraclass correlation coefficients) were computed to quantify consensus strength across the panel.
AASM 2020 Reiteration and Endorsement Framework
In 2016, the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS) issued a joint consensus statement endorsing the NSF recommended ranges for the four adult-age strata: 6-13 years, 14-17 years, 18-64 years, and ≥65 years. The AASM/SRS endorsement was specific to the Recommended column only; the joint statement did not re-grade the May Be Appropriate or Not Recommended columns for those strata. The four pediatric strata (0-3mo, 4-11mo, 1-2y, 3-5y) were not included in the AASM/SRS 2016 endorsement scope and remain solely as the NSF 2015 panel output.
AASM practice parameters and position papers published in 2020 and subsequent clinical practice guidelines have not modified the numerical hour thresholds for the adult strata. The AASM accreditation standards for sleep centers and the clinical practice guideline for the evaluation and management of chronic insomnia disorder reference these duration ranges as the descriptive population-normative framework within which individual clinical assessments are contextualized. The ranges are explicitly described as population-level reference data rather than individually prescriptive targets, consistent with the categorical output of the consensus process.
Duration Definition: TST, TIB, and Nap Inclusion Conventions
The duration unit in all eight age strata of the NSF table is total sleep time (TST), defined as the sum of all epochs scored as any sleep stage (N1, N2, N3, or REM) across the full 24-hour circadian period. TST is operationally distinct from time in bed (TIB), which includes sleep-onset latency, wake-after-sleep-onset (WASO) duration, and any intentional pre-sleep wakefulness in the bed environment. TIB is always numerically greater than or equal to TST; the ratio TST/TIB defines the sleep efficiency metric. Population mean sleep efficiency in healthy young adults is typically reported in the 90-95% range, with expected declines in advanced-age cohorts.
For the four youngest strata through the 3-5 year group, the panel definitions explicitly sum nocturnal consolidated sleep with all daytime nap sleep across the 24-hour period. Napping behavior at these ages is normative: population prevalence of regular napping exceeds 90% at age 12 months, approximately 50-60% at age 36 months, and declines to approximately 10-20% by age 60 months. For the 6-13y stratum and older, the recommended ranges reflect predominantly consolidated nocturnal sleep, reflecting the population-level decline in daytime napping prevalence after early childhood. The table does not partition nighttime versus daytime sleep allocation within any stratum; only the 24-hour TST sum is classified.
Population Distribution and Individual Variation
The three classification columns (Recommended, May Be Appropriate, Not Recommended) represent a consensus-derived categorical system and should not be interpreted as population percentiles. However, large-scale population surveys using polysomnography, wrist actigraphy, and self-report instruments permit comparison of the consensus ranges to empirical sleep duration distributions. In nationally representative adult surveys (e.g., NHIS, BRFSS, NHANES), self-reported usual sleep duration distributions have medians that typically fall within the 7-9 hour Recommended range for the 18-64y stratum, with population standard deviations of approximately 60 to 90 minutes in most cohorts. Approximately two-thirds of adult respondents fall within the 7-9 hour window, approximately 20-25% report durations classified as May Be Appropriate (6 hours or 10 hours), and approximately 10-15% report durations classified as Not Recommended.
Between-individual variation in habitual sleep duration is attributable to a multifactorial set of predictors. Twin and family studies estimate heritability of habitual sleep duration in the 30-40% range, with genome-wide association studies identifying multiple loci of small effect. Significant demographic predictors include age (the primary stratification variable in the table), sex/gender (females report slightly longer mean TST than males in most adult cohorts), socioeconomic status, employment status and work schedule, shift-work exposure, urban versus rural residence, self-reported general health status, and the presence of diagnosed sleep disorders (insomnia, obstructive sleep apnea, restless legs syndrome, circadian rhythm disorders). Pharmacological exposures including sedative-hypnotics, antidepressants, antihypertensives, antihistamines, and stimulant medications also modify TST. The ranges in the table describe population-level expert consensus and do not incorporate adjustment for any of these individual-level covariates.
Data Source References
Eight age strata (0-3mo through ≥65y) × 3 classified columns (Recommended, May Be Appropriate, Not Recommended). Adult strata: AASM/SRS 2016 re-endorsed. AASM 2020 practice parameters: no threshold changes.
- Hirshkowitz M, Whiton K, Albert SM, et al. (2015). National Sleep Foundation's sleep time duration recommendations: methodology and results summary. Sleep Health, 1(1):40-43. Consensus panel methodology and duration table.
- Watson NF, Badr MS, Belenky G, et al. (2015). Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Journal of Clinical Sleep Medicine, 11(6):591-592. AASM/SRS 2016 endorsement of adult ranges.
- RAND Corporation. UCLA Appropriateness Method User's Manual. Standard framework for expert-panel rating methodology used by NSF.
- American Academy of Sleep Medicine. (2020). Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia Disorder in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. Reiteration of adult duration references.